4-(bromomethyl)-4′-chloro-1,1′-biphenyl | 79758-03-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(bromomethyl)-4′-chloro-1,1′-biphenyl
• 英文别名: 4-(Bromomethyl)-4'-chloro-1,1'-biphenyl；1-(bromomethyl)-4-(4-chlorophenyl)benzene
• CAS: 79758-03-5
• 化学式: C₁₃H₁₀BrCl
• 分子量: 281.579
• InChiKey: SJJKBSRJGARHDJ-UHFFFAOYSA-N

物化性质

• 沸点：
  360.3±30.0 °C(Predicted)
• 密度：
  1.435±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  4-(bromomethyl)-4′-chloro-1,1′-biphenyl 在 盐酸 、 sodium hydride 、 sodium cyanoborohydride 作用下， 以 甲醇 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.75h， 生成 N-[3-[[4-(4-chlorophenyl)phenyl]methoxy]phenyl]-1-propan-2-ylpiperidine-4-carboxamide
  参考文献：
  名称：

  Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa

  摘要：

  New chloro-substituted biarylmethoxyphenyl piperidine-4-carboxamides were synthesized and assayed in vitro as inhibitors of the blood coagulation enzymes factor Xa (fXa) and thrombin. An investigation of effects of the amidine and isopropyl groups attached at the piperidine nitrogen and 5-(halogenoaryl)isoxazol-3-yl groups as biaryl substituents led us to identify new compounds which proved to be selective fXa inhibitors, with inhibition constants in the low nanomolar range. The most potent compound 21e, that incorporates 2-Cl-thiophen-5-yl group as the P1 motif and 1-isopropylpiperidine P4 group, inhibited fXa with K-i value of 0.3 nM and very high selectivity over thrombin and some other tested serine proteases, achieving moderate levels of anticoagulant activity in the low micromolar range, as assessed by the prothrombin time clotting assay (PT2 = 3.30 mu M). Based on reliable docking simulations, molecular modeling provided a rationale for interpreting structure-activity relationships. The predicted binding modes highlighted the structural requirements for addressing the subsites S1 and S4 of the fXa enzyme. (C) 2010 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ejps.2010.11.010
• 作为产物：
  描述：

  1-氯-4-(4-甲基苯基)苯 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 四氯化碳 为溶剂， 反应 20.0h， 生成 4-(bromomethyl)-4′-chloro-1,1′-biphenyl
  参考文献：
  名称：

  Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa

  摘要：

  New chloro-substituted biarylmethoxyphenyl piperidine-4-carboxamides were synthesized and assayed in vitro as inhibitors of the blood coagulation enzymes factor Xa (fXa) and thrombin. An investigation of effects of the amidine and isopropyl groups attached at the piperidine nitrogen and 5-(halogenoaryl)isoxazol-3-yl groups as biaryl substituents led us to identify new compounds which proved to be selective fXa inhibitors, with inhibition constants in the low nanomolar range. The most potent compound 21e, that incorporates 2-Cl-thiophen-5-yl group as the P1 motif and 1-isopropylpiperidine P4 group, inhibited fXa with K-i value of 0.3 nM and very high selectivity over thrombin and some other tested serine proteases, achieving moderate levels of anticoagulant activity in the low micromolar range, as assessed by the prothrombin time clotting assay (PT2 = 3.30 mu M). Based on reliable docking simulations, molecular modeling provided a rationale for interpreting structure-activity relationships. The predicted binding modes highlighted the structural requirements for addressing the subsites S1 and S4 of the fXa enzyme. (C) 2010 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ejps.2010.11.010

文献信息

• Discovery and development of substituted tyrosine derivatives as Bcl-2/Mcl-1 inhibitors
  作者：Renshuai Liu、Lulu Liu、Tingting Liu、Xinying Yang、Yichao Wan、Hao Fang

  DOI：10.1016/j.bmc.2018.08.030

  日期：2018.9

  Anti-apoptotic Bcl-2 family proteins are vital for cancer cells to escape apoptosis, which make them attractive targets for cancer therapy. Recently, a lead compound 1 was found to modestly inhibit the binding of BH3 peptide to Bcl-2 protein with a Ki value of 5.2 µM. Based on this, a series of substituted tyrosine derivatives were developed and tested for their binding affinities to Bcl-2 protein

  抗凋亡的Bcl-2家族蛋白对于癌细胞逃避凋亡至关重要，这使其成为癌症治疗的有吸引力的靶标。最近，发现前导化合物1以5.2μM的K i值适度抑制BH3肽与Bcl-2蛋白的结合。基于此，开发了一系列取代的酪氨酸衍生物，并测试了它们与Bcl-2蛋白的结合亲和力。结果表明，这些化合物表现出强效的结合亲和力的Bcl-2和Mcl-1蛋白但不与Bcl-X大号蛋白。可能是化合物6i用K i抑制了BH3肽与Bcl-2和Mcl-1蛋白的结合 分别为450和190nM的值，并且显示出对测试的癌细胞明显的抗增殖活性。
• AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP2725024A1

  公开（公告）日：2014-04-30

  The present invention relates to the filed of pharmarcutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) amd a preparation method thereof, a pharmarcutical composition with the compounds as active components, and a use of the azole compounds and the pharmarcutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as deinfed in the specifictaion.

  本发明涉及药物化学领域，特别是一种由一般式（I）、（II）或（III）表示的新型类唑化合物，以及其制备方法，以这些化合物为活性成分的药物组合物，以及在制备用于治疗与Lp-PLA2酶活性相关疾病的药物中使用这些唑化合物和药物组合物的用途，其中每个取代基如规范中所定义。
• 5-(Substituted)-5-(substitutedsulfonyl or sulfanyl) thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
  申请人：American Cyanamid Company

  公开号：US20030096849A1

  公开（公告）日：2003-05-22

  The invention relates to compounds of Formula (I) wherein R 1 , (R 2 ) v , R 3 and n are defined in the specification and pharmaceutical compositions thereof, that inhibit the Ras farnesyl-protein transferase enzyme (FPTase), and may be used as an alternative to, or in conjunction with, traditional cancer therapy for the treatment of ras oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid. 1

  本发明涉及式（I）的化合物，其中R1，（R2）v，R3和n在规范中定义，并且其制药组合物抑制Ras法尼醇蛋白转移酶（FPTase），可用作替代或与传统癌症治疗相结合，用于治疗ras癌基因依赖性肿瘤，如胰腺癌，结肠癌，膀胱癌和甲状腺癌。
• [EN] AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE AZOLE, PROCÉDÉ DE PRÉPARATION, COMPOSITION PHARMACEUTIQUE ET UTILISATION
  申请人：SHANGHAI INST MATERIA MEDICA

  公开号：WO2013000267A1

  公开（公告）日：2013-01-03

  本发明涉及药物化学领域，尤其涉及一类新颖的通式（I），（II）或（III）所示的唑类化合物及其自备方法，以该类化合物为活性成分的药物组合物，以及它们在制备治疗与Lp-PLA2酶活性有关疾病的药物中的应用。其中，各取代基的定义如说明书中所述。
• Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi
  作者：Sangmi Oh、Sungbum Kim、Sunju Kong、Gyongseon Yang、Nakyung Lee、Dawoon Han、Junghyun Goo、Jair L. Siqueira-Neto、Lucio H. Freitas-Junior、Rita Song

  DOI：10.1016/j.ejmech.2014.07.038

  日期：2014.9

  A high-throughput (HTS) and high-content screening (HCS) campaign of a commercial library identified 2,3-dihydroimidazo[1,2-a]benzimidazole analogues as a novel class of anti-parasitic agents. A series of synthetic derivatives were evaluated for their in vitro anti-leishmanial and anti-trypanosomal activities against Leishmania donovani and Trypanosoma cruzi, which have been known as the causative parasites for visceral leishmaniasis and Chagas disease, respectively. In the case of Leishmania, the compounds were tested in both intracellular amastigote and extracellular promastigote assays. Compounds 4 and 24 showed promising anti-leishmanial activity against intracellular L. donovani (3.05 and 5.29 μM, respectively) and anti-trypanosomal activity against T. cruzi (1.10 and 2.10 μM, respectively) without serious cytotoxicity toward THP-1 and U2OS cell lines.